Shots:

• BMS has exercised its option to an exclusive WW license to a cell therapy based on Obsidian's cytoDRiVE technology for the controlled expression of the immunomodulatory factor CD40L
• In 2019- the companies collaborated to develop novel cell therapies- under which Obsidian is eligible to receive milestones and royalties on sales of therapies. Exercising the option marks BMS’ first opt in decision
• Obsidian's cytoDRiVE technology provides a way to control protein degradation using FDA-approved small molecules- permitting precise control of the timing and level of protein expression

­ Ref: PRNewswire | Image: BMS